MLTXMoonLake Immunotherapeutics
Mkt Cap
$643.27MVolume
606,314.0052W High
$62.7552W Low
$5.95PE Ratio
-3.63MLTX Fundamentals
Price
$10.66Prev Close
$10.20Open
$10.0550D MA
$30.63Beta
0.46Avg. Volume
6.18MEPS (Annual)
-$1.89P/B
1.82Rev/Employee
$0.00MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to...
PR Newswire·17h ago
Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTX
Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTX Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class...
PR Newswire·24h ago
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against MoonLake Immunotherapeutics Class Action: MLTX Stockholders...
PR Newswire·5d ago
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More Shareholders that lost money on MoonLake Immunotherapeutics(MLTX...
PR Newswire·5d ago
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...
Business Wire·6d ago
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman MLTX INVESTOR...
PR Newswire·6d ago
The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTX
The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTX The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class...
PR Newswire·6d ago
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased MoonLake...
Business Wire·7d ago
Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased MoonLake Immunotherapeutics (MoonLake or the Company) (NASDAQ: MLTX...
Business Wire·8d ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming Deadlines - MLTX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming Deadlines - MLTX INVESTOR ALERT: Pomerantz Law...
PR Newswire·8d ago